Cited by 573Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchAmyotrophic Lateral Sclerosis Research

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease

Open access
Bateman, Randall J, Aisen, Paul S, De Strooper, Bart, Fox, Nick C, Lemere, Cynthia A, Ringman, John M, Salloway, Stephen, Sperling, Reisa A +2 more·2010·Alzheimer's Research & Therapy

Abstract

Autosomal-dominant Alzheimer's disease has provided significant understanding of the pathophysiology of Alzheimer's disease. The present review summarizes clinical, pathological, imaging, biochemical, and molecular studies of autosomal-dominant Alzheimer's disease, highlighting the similarities and differences between the dominantly inherited form of Alzheimer's disease and the more common sporadic form of Alzheimer's disease. Current developments in autosomal-dominant Alzheimer's disease are presented, including the international Dominantly Inherited Alzheimer Network and this network's initiative for clinical trials. Clinical trials in autosomal-dominant Alzheimer's disease may test the amyloid hypothesis, determine the timing of treatment, and lead the way to Alzheimer's disease prevention.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/alzrt59

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Colombia has the largest and most homogeneous family group known to have an early-onset (~35 years of age) form of FAD caused by the autosomal dominant and fully penetrant E280A mutation in PSEN1.

    “Interestingly, Colombia has the largest and most homogeneous family group known to have an early‐onset (~35 years of age) form of FAD [54, 59] caused by the autosomal dominant and fully penetrant E280A mutation in PSEN1 [60, 61], which generally produces a more aggressive course of pathology than SAD [55, 56].”

    From Gliovascular alterations in sporadic and familial Alzheimer's disease: <scp><i>APOE3</i></scp> Christchurch homozygote glioprotection (2023) · cites this paper as [59]

    The Clinical presentation of ADAD section says PSEN1-related symptoms typically begin between ages 30 and 50, and the Introduction describes dominantly inherited AD with near-certain disease development in mutation carriers. The paper does not identify a Colombian family as the largest or most homogeneous, give an onset of approximately 35 years for that family, or name the E280A mutation. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • A small subset of Alzheimer's disease cases is caused by autosomal-dominant AD mutations in PSEN1, PSEN2, and APP, leading to early-onset AD with amyloid plaques and neurofibrillary tangles.

    “While most cases are sporadic (SAD), a small subset is caused by autosomal-dominant AD (ADAD) mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP), leading to early-onset AD with hallmark amyloid plaques and neurofibrillary tangles (Bateman et al., 2011; Bird, 2008; Selkoe and Hardy, 2016).”
  • Studies indicate that familial and sporadic Alzheimer's disease have very similar pathogenesis, pathophysiology, and progression.

    “Studies have indicated that the pathogenesis of familial and sporadic Alzheimer’s disease are very similar and share similar pathophysiology and progression36–39.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., Salloway, S., Sperling, R. A., Windisch, M., & Xiong, C.
Affiliations
  • Washington University in St. Louis (US)
  • University of California San Diego (US)
  • UCL Queen Square Institute of Neurology (GB)
  • Brigham and Women's Hospital (US)
  • University of California, Los Angeles (US)
  • Brown University (US)
Corresponding author
Bateman, Randall J
Venue
Alzheimer's Research & Therapy
Published
2010
Volume
3
Issue
1
Pages
1
ISSN
1758-9193 (ISSN-L)
OpenAlex
W2116964904
Cited by
573
References
93
Citations by year
2026: 26 · 2025: 54 · 2024: 49 · 2023: 34 · 2022: 37 · 2021: 63 · 2020: 50 · 2019: 34 · 2018: 36 · 2017: 27 · 2016: 19 · 2015: 30 · 2014: 20 · 2013: 45 · 2012: 29
FWCI
19.89
Type
journal article
Language
en
Open access
Locations
  • Alzheimer s Research & Therapy (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • Lirias (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • National Institute for Health and Care Research (NF-SI-0508-10123)
  • Vlaamse regering
  • National Institutes of Health
  • Medical Research Council
  • National Institute on Aging (U19AG010483, U01AG032438)
  • National Institute of Neurological Disorders and Stroke (R01NS136122)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
autosomal dominant Alzheimer's disease, Alzheimer's disease prevention, amyloid hypothesis, sporadic Alzheimer's disease, clinical trials, pathophysiology, amyloid imaging, treatment timing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review